Enhancing the therapeutic potential of intravenous glycerol for Meniere's disease: Robust results from an extensive patient cohort

Am J Otolaryngol. 2024 Jan-Feb;45(1):104093. doi: 10.1016/j.amjoto.2023.104093. Epub 2023 Oct 18.

Abstract

Introduction: Meniere's disease (MD) is an idiopatic condition characterized by recurrent attacks of vertigo, hearing loss, tinnitus, and aural fullness, affecting quality of life. Intravenous glycerol has shown potential as a therapeutic option. This study evaluates its efficacy in a larger patient cohort.

Materials and methods: Retrospective study with 168 patients having unilateral MD unresponsive to dietary restrictions. Intravenous 10 % glycerol with 0.9 % sodium chloride was administered for six months. Audio-vestibular assessments and questionnaires were used.

Results: Significant improvements in vertigo control observed. 7.1 % achieved complete control, and 58.3 % had substantial control. Quality of life measures improved, and audiometry thresholds remained unchanged. No major adverse events reported.

Discussion: Intravenous glycerol effectively controlled vertigo and improved MD patients' quality of life. Limitations include lack of a control group and a relatively short-term follow-up. Future prospects include randomized controlled trials and optimization of treatment protocols.

Conclusion: Intravenous glycerol shows promise as a therapeutic option for MD, with notable improvements in vertigo control and quality of life. Further research is needed for validation and optimization.

Keywords: Gentamicin; Hearing loss; Intratympanic injection; Meniere disease; Vertigo.

MeSH terms

  • Gentamicins
  • Glycerol
  • Humans
  • Meniere Disease* / drug therapy
  • Quality of Life
  • Retrospective Studies
  • Treatment Outcome
  • Vertigo / drug therapy

Substances

  • Glycerol
  • Gentamicins